Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (3891)	3/4/1998 1:03:00 AM
From: Peter Singleton	Respond to of 6136

Margie, thanks as always, for the great information. As I've posted before, I think AGPH's deal with Roche is as follows: rate a for Viracept sales (for the sake of argument, 15%) a lower rate b for Roche-owned PI sales (for the sake of argument, 10%) btw, I have no idea what the actual rates are. AGPH gets the higher of the two. I'm open to being wrong on this, but this is what I think the deal is. It's an insurance policy against Roche neglecting Viracept, and pushing their own product, but AGPH makes more money if Roche sells Viracept Peter